. 2019 Aug 14;154(11):1014–1021. doi: 10.1001/jamasurg.2019.2979

Table 3. Data for Each Identified Interaction on the PS-Matched Validation Cohort, the Total PS-Matched Cohort, and the Crude Cohort.

Interaction	OR (95% CI)
	Propensity Score Matched Cohort		Crude Cohort Total
	Validation	Total	Crude Cohort Total
Hemiplegia or paraplegia^a^,^b	5.19 (4.37-6.18)	5.35 (4.74-6.05)	18.42 (17.38-19.52)
No solid tumor and WL^a^,^c^,^d	3.49 (2.89-4.22)	3.50 (3.06-4.01)	30.23 (28.72-31.82)
CHF and stage I-IV RD^a^,^c^,^e	3.40 (2.99-3.86)	3.45 (3.15-3.77)	24.66 (23.66-25.71)
Other ND and CHF^a^,^c	2.79 (2.19-3.55)	2.45 (2.06-2.92)	38.15 (35.51-40.99)
No HPTN C and CHF and stage I-V RD^a^,^c	2.75 (2.45-3.08)	2.76 (2.54-2.99)	20.36 (19.62-21.13)
Lymphoma^a^,^f	2.04 (1.66-2.52)	1.93 (1.66-2.23)	2.77 (2.57-3.00)

Abbreviations: CHF, congestive heart failure; HPTN C, complicated hypertension; METS, metastatic cancer; ND, neurologic disorders; OR, odds ratio; PS, propensity score; RD, renal disease; WL, weight loss.

^{^a}

Charlson cormorbidity index.

^{^b}

Also identified, hemiplegia or paraplegia and no solid tumor with METS, or no blood loss anemia, or no liver disease, or no psychoses.

^{^c}

Elixhauser index.

^{^d}

Also identified, WL and no solid tumor with or without METS.

^{^e}

Also identified, stage I to IV RD and no solid tumor with METS.

^{^f}

Also identified, lymphoma and no solid tumor with METS.